Two New Drugs Fight Advanced Melanoma

Wednesday, 29 May 2013 04:56 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
U.S. health regulators approved a pair of drugs to treat advanced melanoma - the deadliest form of skin cancer - in patients with specific genetic mutations. It also approved a diagnostic test to detect the mutations.

The Food and Drug Administration said it approved the drugs, Tafinlar and Mekinist, to be used as single agents and not in combination after the medicines delayed tumor growth in separate clinical trials.
 
After decades with virtually no progress in the fight against advanced melanoma and little to offer patients facing a virtual death sentence, Tafinlar and Mekinist mark the third and fourth new drugs approved by the FDA for metastatic melanoma in the past two years.

Tafinlar, known chemically as dabrafenib, belongs to a class of cancer drugs called as BRAF inhibitors. Mekinist, known chemically as trametinib, inhibits a protein associated with cancerous tumors known as MEK.

Tafinlar was approved to treat patients with melanoma whose tumors express the BRAF V600E gene mutation. Mekinist was approved to treat patients whose tumors express either the BRAF V600E or V600K gene mutations. About half of skin melanomas have a BRAF mutation.

The FDA also approved the THxID BRAF test, made by France's bioMérieux , which will be used to determine if a patient's melanoma cells have the V600E or V600K mutation in the BRAF gene.

Analysts at Cowen and Co forecast sales reaching about $350 million for each drug in 2016.
An estimated 76,690 Americans will be diagnosed with melanoma and 9,480 will die from the disease in 2013, according to the National Cancer Institute.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
You May Also Like

New Painkiller Discourages Abuse

Thursday, 24 Jul 2014 16:38 PM

A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the dr . . .

Zydelig Treats Three Types of Blood Cancer

Wednesday, 23 Jul 2014 17:02 PM

The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences Inc's Zydelig, a drug to treat t . . .

Help for Hereditary Angioedema

Friday, 18 Jul 2014 08:36 AM

Ruconest has been approved by the U.S. Food and Drug Administration to treat hereditary angioedema, a genetic disease th . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved